<p>根據 Nordea Investment Management AB 最近向證券交易委員會（SEC）提交的 13F 表格，該公司在 2023 年第二季度將其在雅培（NYSE:ABT - 免費報告）的持股比例提高了 6.6%。該基金在此期間額外購買了 19,282 股後，持有 310,456 股該醫療產品製造商的股票。Nordea Investment Management AB 在雅培的持股在最近一個季度末價值為 41,921,000 美元。</p>
<p>獲取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>雅培十月股價暴跌是買入信號</li>
</ul>
<p>其他一些機構投資者和對沖基金最近也調整了對該公司的持股。先鋒集團（Vanguard Group Inc.）在第一季度將其在雅培的持股提高了 0.7%。先鋒集團目前擁有 169,823,136 股該醫療產品製造商的股票，價值 22,527,039,000 美元，此前在上個季度又購買了 1,177,739 股。威靈頓管理集團（Wellington Management Group LLP）在第一季度將其在雅培的持股提高了 12.8%。威靈頓管理集團目前擁有 29,763,415 股該醫療產品製造商的股票，價值 3,948,117,000 美元，此前在上個季度又購買了 3,371,113 股。高盛集團（Goldman Sachs Group Inc.）在第一季度將其在雅培的持股提高了 29.2%。高盛集團目前擁有 15,985,797 股該醫療產品製造商的股票，價值 2,120,516,000 美元，此前在上個季度又購買了 3,616,471 股。馬薩諸塞金融服務公司（Massachusetts Financial Services Co. MA）在第一季度將其在雅培的持股提高了 12.8%。馬薩諸塞金融服務公司目前擁有 14,451,305 股該醫療產品製造商的股票，價值 1,916,966,000 美元，此前在上個季度又購買了 1,639,954 股。最後，查爾斯·施瓦布投資管理公司（Charles Schwab Investment Management Inc.）在第一季度將其在雅培的持股提高了 1.3%。查爾斯·施瓦布投資管理公司目前擁有 13,108,416 股該醫療產品製造商的股票，價值 1,738,831,000 美元，此前在上個季度又購買了 168,095 股。75.18% 的股票目前由機構投資者持有。</p>
<h2>內部活動</h2>
<p>在其他消息中，首席財務官 Philip P. Boudreau 於 8 月 8 日星期五出售了 5,550 股公司的股票。該股票以 134.55 美元的平均價格出售，總交易額為 746,752.50 美元。出售完成後，首席財務官直接持有 51,003 股公司的股票，價值為 6,862,453.65 美元。這筆交易代表其持股減少了 9.81%。該出售在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站獲取。0.46% 的股票目前由公司內部人士持有。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>為什麼雅培是 2025 年第二季度的買入：增長與收益</li>
</ul>
<p>雅培成為多份研究分析師報告的主題。摩根士丹利（Morgan Stanley）在 7 月 15 日的報告中將雅培的目標價格從 127.00 美元提高至 137.00 美元，並給予該股票 “持平” 評級。Weiss Ratings 在 10 月 8 日的報告中重申了對雅培股票的 “買入（b）” 評級。桑福德·伯恩斯坦（Sanford C. Bernstein）在週四的報告中將雅培的目標價格從 145.00 美元提高至 150.00 美元，並給予該股票 “跑贏大盤” 評級。威廉·布萊爾（William Blair）在 7 月 17 日的報告中將雅培升級為 “強力買入” 評級。最後，富國銀行（Wells Fargo &amp; Company）在週四的報告中將雅培的目標價格從 142.00 美元提高至 146.00 美元，並給予該股票 “超配” 評級。兩位股票研究分析師對該股票給予了 “強力買入” 評級，十六位分析師給予了 “買入” 評級，四位分析師給予了 “持有” 評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價格為 147.61 美元。</p>
<p><strong>查看我們對雅培的最新分析</strong></p>
<h2>雅培股票表現</h2>
<ul>
<li>如果你想購買 AbbVie 但沒有，現在仍然有機會購買</li>
</ul>
<p>雅培（NYSE:ABT - 獲取免費報告）週五開盤價為 128.69 美元。該公司的流動比率為 1.82，速動比率為 1.30，債務與股本比率為 0.25。該股票的 50 日簡單移動平均線為 132.38 美元，200 日簡單移動平均線為 131.54 美元。雅培的 1 年最低價為 110.86 美元，1 年最高價為 141.23 美元。該股票的市值為 2239.8 億美元，市盈率為 16.13，市盈增長比率為 2.44，貝塔值為 0.69。</p>
<p>雅培（NYSE:ABT - 獲取免費報告）最近於 10 月 15 日發佈了季度財報。該醫療產品製造商報告本季度每股收益為 1.30 美元，符合市場共識預期的 1.30 美元。雅培的股本回報率為 17.78%，淨利潤率為 31.88%。該公司本季度的收入為 113.7 億美元，而分析師預期為 114 億美元。去年同期，該公司的每股收益為 1.21 美元。該公司的收入同比增長了 6.9%。雅培已將其 2025 財年的指導目標設定為每股收益 5.120-5.180 美元。整體來看，分析師預測雅培在當前財年將發佈每股收益 5.14 美元。</p>
<h2>雅培股息公告</h2>
<p>該公司還最近宣佈了一項季度股息，將於 11 月 17 日星期一支付。10 月 15 日星期三的股東將獲得每股 0.59 美元的股息。該股息的除息日期為 10 月 15 日星期三。這代表着每年 2.36 美元的股息和 1.8% 的股息收益率。雅培的股息支付比率（DPR）目前為 29.57%。</p>
<h2>雅培公司簡介</h2>
<p>（免費報告）</p>
<p>雅培（Abbott Laboratories）及其子公司在全球範圍內發現、開發、製造和銷售醫療保健產品。它分為四個業務部門：成熟藥品、診斷產品、營養產品和醫療器械。該公司提供用於治療胰腺外分泌功能不足、腸易激綜合症或膽道痙攣、肝內膽汁淤積或抑鬱症狀、婦科疾病、激素替代療法、血脂異常、高血壓、甲狀腺功能減退、梅尼埃病和前庭性眩暈、疼痛、發熱、炎症和偏頭痛的仿製藥，以及提供抗感染藥物克拉黴素、流感疫苗和調節結腸生理節律的產品。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票，勝過雅培</li>
<li>現在購買的三隻最佳藍籌股</li>
<li>強生的併購策略才是投資者真正關注的故事</li>
<li>三隻天然氣股票提供優厚的股息收益</li>
<li>特斯拉：一些分析師預測將下跌 30%——該恐慌嗎？</li>
<li>股票分析師評級和加拿大分析師評級</li>
<li>對美元的對沖基金態度轉變——這三隻股票的買入信號？</li>
</ul>
<p><strong>想看看其他對雅培持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取雅培（NYSE:ABT - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在雅培嗎？</h2>
<p>在考慮雅培之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前購買的股票……而雅培並不在名單上。</p>
<p>雖然雅培目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

雅培

<p>Nordea Investment Management AB 在第二季度將其在雅培（NYSE:ABT）的持股增加了 6.6%，增持了 19,282 股，總持股達到 310,456 股，價值約為 4190 萬美元。其他機構投資者，包括先鋒集團和高盛，也增加了他們的持股。分析師對雅培的股票給予了積極的評級，普遍目標價為 147.61 美元。該股票開盤價為 128.69 美元，市值為 2239.8 億美元，市盈率為 16.13</p>

<p>Nordea Investment Management AB boosted its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 6.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 310,456 shares of the healthcare product maker's stock after acquiring an additional 19,282 shares during the period. Nordea Investment Management AB's holdings in Abbott Laboratories were worth $41,921,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根據 Nordea Investment Management AB 最近向證券交易委員會（SEC）提交的 13F 表格，該公司在 2023 年第二季度將其在雅培（NYSE:ABT - 免費報告）的持股比例提高了 6.6%。該基金在此期間額外購買了 19,282 股後，持有 310,456 股該醫療產品製造商的股票。Nordea Investment Management AB 在雅培的持股在最近一個季度末價值為 41,921,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>Abbott Laboratories' October Price Plunge Is a Signal to Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培十月股價暴跌是買入信號</li>
</ul>
</div><p>A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in shares of Abbott Laboratories by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 169,823,136 shares of the healthcare product maker's stock worth $22,527,039,000 after buying an additional 1,177,739 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Abbott Laboratories by 12.8% during the 1st quarter. Wellington Management Group LLP now owns 29,763,415 shares of the healthcare product maker's stock worth $3,948,117,000 after buying an additional 3,371,113 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Abbott Laboratories by 29.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 15,985,797 shares of the healthcare product maker's stock worth $2,120,516,000 after buying an additional 3,616,471 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in shares of Abbott Laboratories by 12.8% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 14,451,305 shares of the healthcare product maker's stock worth $1,916,966,000 after buying an additional 1,639,954 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Abbott Laboratories by 1.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 13,108,416 shares of the healthcare product maker's stock worth $1,738,831,000 after buying an additional 168,095 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些機構投資者和對沖基金最近也調整了對該公司的持股。先鋒集團（Vanguard Group Inc.）在第一季度將其在雅培的持股提高了 0.7%。先鋒集團目前擁有 169,823,136 股該醫療產品製造商的股票，價值 22,527,039,000 美元，此前在上個季度又購買了 1,177,739 股。威靈頓管理集團（Wellington Management Group LLP）在第一季度將其在雅培的持股提高了 12.8%。威靈頓管理集團目前擁有 29,763,415 股該醫療產品製造商的股票，價值 3,948,117,000 美元，此前在上個季度又購買了 3,371,113 股。高盛集團（Goldman Sachs Group Inc.）在第一季度將其在雅培的持股提高了 29.2%。高盛集團目前擁有 15,985,797 股該醫療產品製造商的股票，價值 2,120,516,000 美元，此前在上個季度又購買了 3,616,471 股。馬薩諸塞金融服務公司（Massachusetts Financial Services Co. MA）在第一季度將其在雅培的持股提高了 12.8%。馬薩諸塞金融服務公司目前擁有 14,451,305 股該醫療產品製造商的股票，價值 1,916,966,000 美元，此前在上個季度又購買了 1,639,954 股。最後，查爾斯·施瓦布投資管理公司（Charles Schwab Investment Management Inc.）在第一季度將其在雅培的持股提高了 1.3%。查爾斯·施瓦布投資管理公司目前擁有 13,108,416 股該醫療產品製造商的股票，價值 1,738,831,000 美元，此前在上個季度又購買了 168,095 股。75.18% 的股票目前由機構投資者持有。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In other news, CFO Philip P. Boudreau sold 5,550 shares of the firm's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the sale, the chief financial officer directly owned 51,003 shares of the company's stock, valued at $6,862,453.65. This trade represents a 9.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.46% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，首席財務官 Philip P. Boudreau 於 8 月 8 日星期五出售了 5,550 股公司的股票。該股票以 134.55 美元的平均價格出售，總交易額為 746,752.50 美元。出售完成後，首席財務官直接持有 51,003 股公司的股票，價值為 6,862,453.65 美元。這筆交易代表其持股減少了 9.81%。該出售在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站獲取。0.46% 的股票目前由公司內部人士持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>Why Abbott Laboratories Is a Q2 2025 Buy: Growth &amp; Yield</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼雅培是 2025 年第二季度的買入：增長與收益</li>
</ul>
</div><p>ABT has been the topic of a number of research analyst reports. Morgan Stanley increased their price target on Abbott Laboratories from $127.00 to $137.00 and gave the stock an &#34;equal weight&#34; rating in a report on Tuesday, July 15th. Weiss Ratings reiterated a &#34;buy (b)&#34; rating on shares of Abbott Laboratories in a report on Wednesday, October 8th. Sanford C. Bernstein increased their target price on Abbott Laboratories from $145.00 to $150.00 and gave the stock an &#34;outperform&#34; rating in a report on Thursday. William Blair upgraded Abbott Laboratories to a &#34;strong-buy&#34; rating in a report on Thursday, July 17th. Finally, Wells Fargo &amp; Company increased their target price on Abbott Laboratories from $142.00 to $146.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $147.61.</p>
<div class="lb-trans"><p>雅培成為多份研究分析師報告的主題。摩根士丹利（Morgan Stanley）在 7 月 15 日的報告中將雅培的目標價格從 127.00 美元提高至 137.00 美元，並給予該股票 “持平” 評級。Weiss Ratings 在 10 月 8 日的報告中重申了對雅培股票的 “買入（b）” 評級。桑福德·伯恩斯坦（Sanford C. Bernstein）在週四的報告中將雅培的目標價格從 145.00 美元提高至 150.00 美元，並給予該股票 “跑贏大盤” 評級。威廉·布萊爾（William Blair）在 7 月 17 日的報告中將雅培升級為 “強力買入” 評級。最後，富國銀行（Wells Fargo &amp; Company）在週四的報告中將雅培的目標價格從 142.00 美元提高至 146.00 美元，並給予該股票 “超配” 評級。兩位股票研究分析師對該股票給予了 “強力買入” 評級，十六位分析師給予了 “買入” 評級，四位分析師給予了 “持有” 評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價格為 147.61 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Abbott Laboratories</strong></p>
<div class="lb-trans"><p><strong>查看我們對雅培的最新分析</strong></p>
</div><h2>Abbott Laboratories Price Performance</h2>
<div class="lb-trans"><h2>雅培股票表現</h2>
</div><ul>
<li>If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>如果你想購買 AbbVie 但沒有，現在仍然有機會購買</li>
</ul>
</div><p>Shares of NYSE:ABT opened at $128.69 on Friday. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The stock's fifty day simple moving average is $132.38 and its two-hundred day simple moving average is $131.54. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23. The stock has a market cap of $223.98 billion, a PE ratio of 16.13, a price-to-earnings-growth ratio of 2.44 and a beta of 0.69.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 獲取免費報告）週五開盤價為 128.69 美元。該公司的流動比率為 1.82，速動比率為 1.30，債務與股本比率為 0.25。該股票的 50 日簡單移動平均線為 132.38 美元，200 日簡單移動平均線為 131.54 美元。雅培的 1 年最低價為 110.86 美元，1 年最高價為 141.23 美元。該股票的市值為 2239.8 億美元，市盈率為 16.13，市盈增長比率為 2.44，貝塔值為 0.69。</p>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, meeting the consensus estimate of $1.30. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.The business had revenue of $11.37 billion for the quarter, compared to analysts' expectations of $11.40 billion. During the same period last year, the business earned $1.21 EPS. The business's revenue was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 獲取免費報告）最近於 10 月 15 日發佈了季度財報。該醫療產品製造商報告本季度每股收益為 1.30 美元，符合市場共識預期的 1.30 美元。雅培的股本回報率為 17.78%，淨利潤率為 31.88%。該公司本季度的收入為 113.7 億美元，而分析師預期為 114 億美元。去年同期，該公司的每股收益為 1.21 美元。該公司的收入同比增長了 6.9%。雅培已將其 2025 財年的指導目標設定為每股收益 5.120-5.180 美元。整體來看，分析師預測雅培在當前財年將發佈每股收益 5.14 美元。</p>
</div><h2>Abbott Laboratories Dividend Announcement</h2>
<div class="lb-trans"><h2>雅培股息公告</h2>
</div><p>The firm also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be given a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. Abbott Laboratories's dividend payout ratio (DPR) is currently 29.57%.</p>
<div class="lb-trans"><p>該公司還最近宣佈了一項季度股息，將於 11 月 17 日星期一支付。10 月 15 日星期三的股東將獲得每股 0.59 美元的股息。該股息的除息日期為 10 月 15 日星期三。這代表着每年 2.36 美元的股息和 1.8% 的股息收益率。雅培的股息支付比率（DPR）目前為 29.57%。</p>
</div><h2>Abbott Laboratories Company Profile</h2>
<div class="lb-trans"><h2>雅培公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p>
<div class="lb-trans"><p>雅培（Abbott Laboratories）及其子公司在全球範圍內發現、開發、製造和銷售醫療保健產品。它分為四個業務部門：成熟藥品、診斷產品、營養產品和醫療器械。該公司提供用於治療胰腺外分泌功能不足、腸易激綜合症或膽道痙攣、肝內膽汁淤積或抑鬱症狀、婦科疾病、激素替代療法、血脂異常、高血壓、甲狀腺功能減退、梅尼埃病和前庭性眩暈、疼痛、發熱、炎症和偏頭痛的仿製藥，以及提供抗感染藥物克拉黴素、流感疫苗和調節結腸生理節律的產品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>Johnson &amp; Johnson's M&amp;A Strategy Is the Real Story for Investors</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?</li>
<li>Stock Analyst Ratings and Canadian Analyst Ratings</li>
<li>Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過雅培</li>
<li>現在購買的三隻最佳藍籌股</li>
<li>強生的併購策略才是投資者真正關注的故事</li>
<li>三隻天然氣股票提供優厚的股息收益</li>
<li>特斯拉：一些分析師預測將下跌 30%——該恐慌嗎？</li>
<li>股票分析師評級和加拿大分析師評級</li>
<li>對美元的對沖基金態度轉變——這三隻股票的買入信號？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對雅培持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取雅培（NYSE:ABT - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在雅培嗎？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮雅培之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前購買的股票……而雅培並不在名單上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然雅培目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Nordea Investment Management AB 購入了雅培公司 19,282 股股票